Why Is HAEMONETICS CORP MAS (HAE) Stock Up Today?

Haemonetics stock (HAE) surged 17.46% to close at $119.47, marking a new 52-week high. The primary driver for the move was the announcement of an expanded supply agreement with CSL Plasma, which significantly broadens the scope of the companies' existing partnership.

What Happened

Haemonetics disclosed a new SEC filing detailing a supply agreement with CSL Plasma. Under the terms of the deal, CSL Plasma plans to utilize Haemonetics’ plasma collection equipment across all of its existing U.S. centers. This arrangement expands the scope of an earlier supply agreement, opening the door to additional revenue streams for the medical technology company. The announcement prompted immediate positive reactions from financial analysts. BTIG raised its price target for Haemonetics to $130 from $110 while maintaining a Buy rating on the stock. The firm cited the CSL Plasma deal as a key catalyst for the upward revision.

What The Data Shows

The stock printed seven fresh 52-week highs on October 8, 2026, breaking through its previous high of $110.45. Over the last eight trading sessions, the stock has accumulated a gain of 12.9%, moving from $105.80 to the current close. Fundamentals indicate a market capitalization of $4.7 billion with a trailing P/E ratio of 49.4. The company reported a net margin of 7.1% and revenue growth of 0.4% on a trailing twelve-month basis. With a beta of 0.61, the stock has historically exhibited lower volatility than the broader market. The 52-week range spans from $48.17 to the new high of $119.47.

What To Watch

Investors will monitor the broader healthcare sector for similar partnership announcements, as the move coincided with other notable deals in the space. The stock’s recent momentum and elevated valuation relative to its revenue growth will likely remain focal points for analysts in the coming weeks.